[ad_1]

WALTHAM, Mass., Oct. 30, 2023 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (“Aeglea”) (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced that management…

[ad_2]